Achalasia, a chronic oesophageal motility disorder, is defined by impaired lower oesophageal sphincter relaxation and absent peristalsis, leading to symptoms such as dysphagia and regurgitation.

a drug candidate that is trying to be the first approved therapy in the US for eosinophilic oesophagitis (EoE). Takeda said it had received a complete response letter from the US regulator that is ...

The company has secured $100 million upfront – with the remaining $160 million due if the erosive oesophagitis approval comes through – from Sagard Healthcare Partners, NovaQuest Capital ...

The first PPI to reach the market was omeprazole, which is indicated for the treatment of duodenal and gastric ulcers, gastro-oesophageal reflux disease, erosive oesophagitis, hypersecretory ...

From wetting the bed to acne, we have crunched the numbers on the success rate of every single disability claim. It comes ...